Cardiac involvement in polymyositis has recently been found to be more prevalent than had been believed, and its clinical spectrum to be wide and variable. Recent studies suggest that cardiac abnormalities are seen in approximately 75% of patients with polymyositis. The usual manifestations are congestive heart failure, arrhythmias, heart blocks, and electrocardiographic abnormalities. This case report describes the diagnosis and clinical course of cardiac polymyositis in a 57-year-old woman.
stolic pressure was 24 mm Hg, and she was diagnosed as having primary myocardial disease. A Holter monitor reading, obtained in 1976, revealed sinus rhythm with occasional ventricular ectopy and paroxysms of atrial fibrillation. She was treated with propranolol and digoxin with some benefit. However, she developed a rash while taking quinidine and could not tolerate procainamide. At the time of her visit to the Cleveland Clinic, she was on disopyramide, propranolol, and digoxin.
Physical examination in December 1980 revealed an anxious white woman with an irregular pulse of 80 beat/min. Blood pressure was 150/90 mm Hg. There was no jugular venous distention. The lungs were clear. Heart examination revealed the point of maximal intensity (PMI) in the fifth left intercostal space at the anterior axillary line. The first heart sound (SI) varied in intensity, and the second heart sound (S2) appeared normal. A third heart sound (S3) was heard at the apex. There was no fourth heart sound (S4). The abdomen was soft and nontender without masses or distention. A slight decrease in motor strength was noted in both upper and lower extremities.
Laboratory studies disclosed the following results: complete blood count (CBC) was normal. 
Discussion
Polymyositis was first described by Wagner in 1886. 3 The clinical syndrome refers to an inflammatory myopathy of unknown cause, characterized by weakness of the proximal muscles of the pelvis and shoulder girdle. The incidence is 0.1-0.6/100,000 persons per year. 4 It is most common in those between 40 and 60 years of age and in females (female to male ratio, 2: l). 4 Underlying malignancy is noted in 10% to 15% of cases, 4 common malignancies being those of the stomach, colon, rectum, and ovaries. Steroids are the mainstay of therapy. Methotrexate and azathioprine are used with variable success.
Cardiac involvement was first described by Oppenheim in 1899. 5 Reported ECG abnormalities are first-, second-, and third-degree heart blocks, bundle branch blocks, left axis deviations, and atrial and ventricular dysrhythmias.
1 ' 6 Myocardial involvement with congestive heart failure 7 and pericardial involvement with pericarditis 8 are common.
Age distribution and sex incidence follow the classic concept of polymyositis, which is predominately a disease of middle-aged women. Female to male ratio is 2:1, and the mean age ranges from 44 to 53 years.
1,2 Cardiovascular symptoms as presenting complaints are clinically apparent in only 10% to 15% of biopsy-proved polymyositis, even though cardiac involvement is seen in 70% of the cases. 1 This suggests symptomatic cardiac involvement is infrequent. Presenting cardiovascular manifestations are palpitations, nonspecific chest pain, congestive heart failure, and systolic murmur of mitral regurgitation.
1,2
In a prospective study done on 21 patients at George Washington Hospital, 1 the frequency of cardiovascular involvement discovered with noninvasive techniques appeared to be high. Echocardiogram, phonocardiogram, and ECG were done on all patients studied, more than one half of whom were female. Fifty percent had ECG abnormalities, 33% had an ejection click and systolic murmur on phonocardiogram, and 50% had mitral valve prolapse on echocardiogram. All patients in that study had normal left ventricular end-diastolic dimensions. It is also reported that the mean velocity of circumferential fiber shortening and fractional shortening was greater than for the control group, which is suggestive of high cardiac output. One of the patients underwent cardiac catheterization, and the hemodynamic data, which tend to support this, show a CI of 6.8 lit/m 2 (4 lit) and stroke volume (SV) index of 90.5 ml (40 ml). The cause of this high output remains unclear. Postulated mechanisms include: (1) increased metabolic demand, (2) increased AV shunting in the affected muscles, and (3) production of a vasoactive amine. 9 In a clinicopathologic study done at The Mayo Clinic on 20 patients, 2 40% had clinical evidence of congestive heart failure, 45% had abnormal chest radiographs, 72% had ECG abnormalities, and the female to male ratio was 2:1. At autopsy the mean heart weight was 355 g compared to 405 g in controls. Histological evidence of myocarditis and small vessel disease was present in 30% of patients. Diffuse interstitial and perivascular mononuclear cell infiltrate was present. Muscle degeneration and fibrous replacement of sinoatrial (SA) node and bundle branches were noted. In a study done in Finland, 10 69% of the patients showed cardiac involvement. An interesting finding in this study involves a group of 6 patients who also had coronary artery disease in addition to polymyositis. In 5, angina symptoms appeared after polymyositis was diagnosed. Three had myocardial infarctions, and 2 died. At autopsy, no scar of myocardial infarction or arteriosclerosis was found. Macroscopically the changes in the coronary arteries are suggestive of polymyositis involvement. None of these patients had coronary arteriography. The ECG changes could be secondary to myopathy.
All the classic manifestations of cardiac involvement in polymyositis, namely, abnormal ECG, atrial and ventricular arrhythmias, varying degrees of heart block, and left ventricular dysfunction were noted in this case. There was no evidence of ischemic or other etiologic factors to account for the cardiac abnormalities. Myocardial biopsy would have been helpful in establishing a definitive diagnosis, but it was refused by the patient. However, the combination of elevated muscle enzymes, abnormal electromyography suggestive of polymyositis, typical skeletal muscle biopsy findings, and myocardial disease strongly suggests that the cardiomyopathic process represents involvement secondary to polymyositis. It is extremely rare for polymyositis to present in this way, because the clinical picture was dominated by cardiac abnormalities and skeletal muscle involvement was of minor clinical importance.
Cardiac involvement in polymyositis is frequent, and the clinical spectrum is wide and variable. Available data are incomplete and inconclusive. Further studies are needed to evaluate the natural history, detection, management, and prognosis of the disease and to prevent myocardial involvement. The role of antiarrhythmic drugs, steroids, and immunosuppressive drugs should be assessed.
